Central to our investment strategy is active involvement with our portfolio Companies. We constantly look for opportunities to add value to our Companies, through our shared knowledge base and experience, or by drawing on our network of international experts. We engage in strategic decision making on issues ranging from (pre)clinical development programmes, to evaluating business development opportunities and financial guidance. Our background provides us with a solid experience and good inroads into the financial community, leading to excellent support in M&A and IPO processes.
To date, Forbion has built a strong, well-balanced, transatlantic portfolio through investments in most segments and stages of drug and medical device development.
Our track record confirms that we select companies with a strong capability to develop products, and that are responsive to the changing nature of the life sciences industry. This has ensured successful exits in the form of trade sales and IPO's resulting in optimal growth of our investments.